ACM
TXG icon

Aster Capital Management’s 10x Genomics TXG Stock Holding History

Aster Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-53
Closed -$1.2K – 1535
2024
Q3 		$1.2K Buy
+53
New +$1.1K ﹤0.01% 1006

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aster Capital Management's TXG Position: Q4 2024 in Review

Aster Capital Management sold out of 10x Genomics (TXG) in Q4 2024, closing a stake of 53 shares — an estimated $1.2K sold.

Aster Capital Management first reported a position in TXG in Q3 2024 and held it in 1 quarter. The position peaked at $1.2K in Q3 2024. 273 funds tracked by Wall St. Rank hold TXG as of Q4 2024.

  • Aster Capital Management reported no remaining 10x Genomics position as of Q4 2024 after selling out during the quarter.
  • Aster Capital Management sold 53 10x Genomics shares in Q4 2024, an estimated $1.2K.
  • Aster Capital Management first reported a position in 10x Genomics in Q3 2024 and held it in 1 quarter.
  • Aster Capital Management's 10x Genomics position peaked at $1.2K in Q3 2024.
  • 273 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2024.

Based on Aster Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.